Tirzepatide [2023788-19-2] [2023788-19-2]

AdipoGen Life Sciences

Tirzepatide [2023788-19-2] [2023788-19-2]

10

2023788-19-2

Research Use Only

>98%

C225H348N48O68

4813.5

Chemical. CAS: 2023788-19-2. Formula: C225H348N48O68. MW: 4813.5. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Tirzepatide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains two non-coded amino acid residues (Aib, alpha-amino isobutyric acid) at positions 2 and 13). - Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R. Tirzepatide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. Tirzepatide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes. Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 20. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains two non-coded amino acid residues (Aib, alpha-amino isobutyric acid) at positions 2 and 13).

N[C@H](C(NC(C)(C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@H](O)C)([H])C(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@]([C@@H](C)CC)([H])C(NC(C)(C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CCCCN)C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@]([C@@H](C)CC)([H])C(N[C@H](C(NCC(NCC(N1CCC[C@H]1C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@H](C(N2CCC[C@H]2C(N3CCC[C@H]3C(N4CCC[C@H]4C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)C)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O)=O)=O)CC7=CC=CC=C7)=O)C)=O)=O)=O)C)=O)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)CC(C=C8)=CC=C8O)=O)CC(O)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)=O)CC%10=CC=C(O)C=C%10

-20°C,2°C to 8°C

12352200